‘New dawn’ for spinal muscular atrophy treatment
Nusinersen has shown promise as a treatment for infantile-onset spinal muscular atrophy, improving muscle function and nerve activity, show phase II study findings published in The Lancet.
Osimertinib outplays chemotherapy in EGFR T790M-positive advanced NSCLC
The third-generation tyrosine kinase inhibitor osimertinib significantly improves outcomes relative to platinum-based chemotherapy plus pemetrexed in advanced non-small-cell lung cancer patients who have acquired the epidermal growth factor receptor T790M mutation after initial treatment with an EGFR TKI, show the AURA3 results.
Headlines from across medwireNews
Beyond the news
medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.
Click through to read the full reports of the latest research.
Highlights from the 1st conference of the European Academy of Neurology in Berlin, Germany.
Click through to read research news from the conference.
medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make medwireNews.com your preferred medical news resource.
Blood clot/© Eraxion / Getty Images / iStock, Baby_grasping toe/© tan4ikk / Fotolia, lung_cancer, ESMO 2016 flags_enhanced/© Lynda Williams, Children with medical team/© Christopher Futcher, Brandenburg Gate/© Nikada/iStock, Lucy Piper, Lynda Williams, Eleanor McDermid, Shreeya Nanda, Claire Barnard, Alison Chapman, Kamran Ahmad